Ken Griffin Emergent Bio Solutions Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$1.86 - $6.98 $37,944 - $142,392	-20,400 Reduced 63.75%	11,600 $79,000
Q1 2024 May 15, 2024	SELL	$1.5 - $3.41 $2,550 - $5,797	-1,700 Reduced 5.04%	32,000 $80,000
Q4 2023 Feb 14, 2024	BUY	$1.82 - $3.16 $4,914 - $8,532	2,700 Added 8.71%	33,700 $80,000
Q3 2023 Nov 14, 2023	SELL	$3.17 - $7.91 $50,403 - $125,769	-15,900 Reduced 33.9%	31,000 $105,000
Q2 2023 Aug 14, 2023	SELL	$7.35 - $13.21 $385,140 - $692,204	-52,400 Reduced 52.77%	46,900 $344,000
Q1 2023 May 15, 2023	BUY	$7.79 - $16.29 $617,747 - $1.29 Million	79,300 Added 396.5%	99,300 $1.03 Million
Q4 2022 Feb 14, 2023	BUY	$11.0 - $21.45 $92,400 - $180,180	8,400 Added 72.41%	20,000 $236,000
Q3 2022 Nov 14, 2022	SELL	$20.09 - $35.8 $658,952 - $1.17 Million	-32,800 Reduced 73.87%	11,600 $243,000

154

30.2M

137K

706K

Ticker EBS
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,861,500
Market Cap $349M
Description
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.